Tatsuya Minami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3793331/publications.pdf

Version: 2024-02-01

623734 454955 1,178 30 14 30 citations g-index h-index papers 30 30 30 2204 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut, 2022, 71, 593-604.	12.1	62
2	Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan. Journal of Hepatology, 2022, , .	3.7	1
3	Improved prognosis of hepatitis Câ€related hepatocellular carcinoma in the era of directâ€acting antivirals. Hepatology Communications, 2022, 6, 2496-2512.	4.3	4
4	Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). Journal of Gastroenterology, 2022, 57, 587-597.	5.1	5
5	Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma. Journal of Gastroenterology, 2021, 56, 456-469.	5.1	11
6	Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals. Liver Cancer, 2021, 10, 309-319.	7.7	16
7	Radiofrequency Ablation of Liver Tumors in Patients on Antithrombotic Therapy: A Case-Control Analysis of over 10,000 Treatments. Journal of Vascular and Interventional Radiology, 2021, 32, 869-877.	0.5	3
8	Limited efficacy of atezolizumab and bevacizumab for hepatocellular carcinoma previously treated with tyrosine kinase inhibitor. Liver International, 2021, 41, 2233-2234.	3.9	6
9	Infectious complications related to radiofrequency ablation of liver tumors: The role of antibiotics. PLoS ONE, 2021, 16, e0259641.	2.5	2
10	Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients. Journal of Gastroenterology, 2020, 55, 227-243.	5.1	29
11	Chronological change in alphaâ€fetoprotein levels in hepatocellular carcinoma after eradication of hepatitis C virus. Liver International, 2020, 40, 2305-2306.	3.9	1
12	Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume. PLoS ONE, 2020, 15, e0231836.	2.5	6
13	A Novel Non-invasive Method for Predicting Liver Fibrosis by Quantifying the Hepatic Vein Waveform. Ultrasound in Medicine and Biology, 2019, 45, 2363-2371.	1.5	6
14	Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. Scientific Reports, 2019, 9, 10663.	3.3	57
15	Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. Journal of Hepatology, 2019, 71, 473-485.	3.7	62
16	Ischemic complications after percutaneous radiofrequency ablation of liver tumors: Liver volume loss and recovery. Hepatology Research, 2019, 49, 453-461.	3.4	4
17	Liver stiffness measurements in chronic hepatitis C: Treatment evaluation and risk assessment. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 921-928.	2.8	18
18	Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy. Journal of Hepatology, 2019, 70, 78-86.	3.7	71

#	Article	IF	CITATION
19	Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation. PLoS ONE, 2018, 13, e0200943.	2.5	4
20	Hepatic IRS1 and $\tilde{A}\ddot{V}$ -catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients. Journal of Gastroenterology, 2018, 53, 1261-1275.	5.1	25
21	The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. Journal of Hepatology, 2016, 65, 1272-1273.	3.7	79
22	Impact of serum ferritin level on hepatocarcinogenesis in chronic hepatitis C patients. Hepatology Research, 2016, 46, 259-268.	3.4	13
23	Slight elevation of highâ€sensitivity <scp>C</scp> â€reactive protein to predict recurrence and survival in patients with early stage hepatitis <scp>C</scp> â€related hepatocellular carcinoma. Hepatology Research, 2015, 45, 645-655.	3.4	10
24	Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients. Medicine (United States), 2015, 94, e901.	1.0	16
25	Comparison of improved prognosis between hepatitis B†and hepatitis C†elated hepatocellular carcinoma. Hepatology Research, 2015, 45, E99-E107.	3.4	15
26	Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. Journal of Hepatology, 2015, 63, 131-140.	3.7	538
27	Spontaneous clearance of serum hepatitis <scp>C</scp> virus <scp>RNA</scp> during the clinical course of hepatocellular carcinoma in patients with chronic hepatitis <scp>C</scp> . Hepatology Research, 2014, 44, E32-7.	3.4	8
28	Frequency of and Predictive Factors for Vascular Invasion after Radiofrequency Ablation for Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e111662.	2.5	24
29	Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. Journal of Gastroenterology, 2013, 48, 254-268.	5.1	21
20	DNA Mathylation Pagulatas Placantal Lactoren I Cana Expression, Endocrinology, 2001, 142, 3389,3396	20	61